DE69033600T2 - Verfahren zur Isolierung von Haemopnilus influenzae Protein-E - Google Patents

Verfahren zur Isolierung von Haemopnilus influenzae Protein-E

Info

Publication number
DE69033600T2
DE69033600T2 DE69033600T DE69033600T DE69033600T2 DE 69033600 T2 DE69033600 T2 DE 69033600T2 DE 69033600 T DE69033600 T DE 69033600T DE 69033600 T DE69033600 T DE 69033600T DE 69033600 T2 DE69033600 T2 DE 69033600T2
Authority
DE
Germany
Prior art keywords
haemopnilus
isolation
extracting
protein
influenzae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69033600T
Other languages
English (en)
Other versions
DE69033600D1 (de
Inventor
Bruce A Green
Gary W Zlotnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of DE69033600D1 publication Critical patent/DE69033600D1/de
Publication of DE69033600T2 publication Critical patent/DE69033600T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69033600T 1989-03-09 1990-03-09 Verfahren zur Isolierung von Haemopnilus influenzae Protein-E Expired - Lifetime DE69033600T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32097189A 1989-03-09 1989-03-09

Publications (2)

Publication Number Publication Date
DE69033600D1 DE69033600D1 (de) 2000-09-07
DE69033600T2 true DE69033600T2 (de) 2001-04-05

Family

ID=23248627

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69033600T Expired - Lifetime DE69033600T2 (de) 1989-03-09 1990-03-09 Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
DE69012318T Expired - Lifetime DE69012318T2 (de) 1989-03-09 1990-03-09 Impfstoffe gegen hämophilus influenzae.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69012318T Expired - Lifetime DE69012318T2 (de) 1989-03-09 1990-03-09 Impfstoffe gegen hämophilus influenzae.

Country Status (13)

Country Link
US (4) US5601831A (de)
EP (2) EP0606921B1 (de)
JP (1) JP2955014B2 (de)
KR (1) KR100188323B1 (de)
AT (2) ATE195076T1 (de)
AU (1) AU648251B2 (de)
CA (1) CA2047681C (de)
DE (2) DE69033600T2 (de)
DK (2) DK0606921T3 (de)
ES (2) ES2150450T3 (de)
FI (1) FI914241A0 (de)
NO (1) NO913518L (de)
WO (1) WO1990010458A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340888C (en) * 1988-09-01 2000-02-01 Algis Anilionis Vaccines and diagnostic assays for haemophilus influenzae
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
WO1993008290A1 (en) * 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
ES2145072T3 (es) * 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
CA2218385A1 (en) * 1995-04-17 1996-10-24 Pierre Hauser Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
AR003125A1 (es) * 1995-06-01 1998-07-08 Astra Ab Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
GB9513074D0 (en) * 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
WO2002089839A1 (en) * 2001-05-03 2002-11-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
US20040126381A1 (en) * 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
ES2270537T3 (es) * 1997-11-12 2007-04-01 F. Hoffmann-La Roche Ag Tratamiento de enfermedades inmunes mediadas por celulas t ayudantes de tipo 2.
US6255050B1 (en) * 1998-05-22 2001-07-03 Lorne Park Research, Inc. Dynamic hybridization system
US7553634B1 (en) 1999-06-25 2009-06-30 Wyeth Holdings Corporation Extraction of integral membrane proteins
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
US6391313B1 (en) * 1999-07-15 2002-05-21 Aventis Pasteur Limited Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
JP2003507433A (ja) * 1999-08-20 2003-02-25 ザ ゼネラル ホスピタル コーポレーション 敗血症治療において治療に用いる対象としての外膜タンパク質ａ、ペプチドグリカン関連リポタンパク質およびムレインリポタンパク質
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AU8640501A (en) * 2000-07-31 2002-02-13 Univ Yale Innate immune system-directed vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
GB0025486D0 (en) * 2000-10-17 2000-11-29 Smithkline Beecham Biolog Novel compounds
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US6834384B2 (en) * 2001-03-14 2004-12-21 General Instrument Corporation Methods and apparatus for upgrading firmware in an embedded system
CA2449670A1 (en) * 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
DE60234695D1 (de) 2001-06-07 2010-01-21 Univ Colorado Mutantenformen von cholera holotoxin als adjuvans
WO2002100891A2 (en) * 2001-06-12 2002-12-19 Glaxosmithkline Biologicals S.A. Proteins derived from non-typable haemophilus influenzae (nthi) strain
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003078453A1 (en) 2002-03-15 2003-09-25 Wyeth Holdings Corporation Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
KR20070047455A (ko) * 2005-11-02 2007-05-07 삼성에스디아이 주식회사 전자 방출 표시 디바이스
WO2007103322A2 (en) * 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
PT1915913E (pt) * 2006-10-23 2016-02-16 Nestec Sa Modulação do sabor e do aroma de produtos lácteos por biotransformação
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
KR20110111381A (ko) * 2009-01-07 2011-10-11 오츠카 세이야쿠 가부시키가이샤 전 인플루엔자균의 측정방법
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
TW201302779A (zh) * 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US9822150B2 (en) 2013-09-08 2017-11-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220717A (en) * 1977-12-22 1980-09-02 American Cyanamid Company Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4220722A (en) * 1978-02-10 1980-09-02 Syva Company Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4661347A (en) 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4873090A (en) * 1985-03-27 1989-10-10 Broncostat Pty. Limited Non-adjuvenated vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JP2534529B2 (ja) * 1986-07-24 1996-09-18 ブリティシュ・テレコミュニケ−ションズ・パブリック・リミテッド・カンパニ 放射発生器
US5173294A (en) * 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
AU623353B2 (en) * 1987-12-10 1992-05-14 Board Of Regents, The University Of Texas System Methods and compositions for the production of haemophilus influenzae type b major outer membrane protein antigens

Also Published As

Publication number Publication date
CA2047681C (en) 2000-02-01
DK0462210T3 (da) 1994-10-10
ES2063965T3 (es) 1995-01-16
AU648251B2 (en) 1994-04-21
US5955580A (en) 1999-09-21
ES2150450T3 (es) 2000-12-01
FI914241A0 (fi) 1991-09-09
EP0462210A1 (de) 1991-12-27
DE69012318T2 (de) 1995-03-09
KR100188323B1 (ko) 1999-06-01
JP2955014B2 (ja) 1999-10-04
ATE195076T1 (de) 2000-08-15
US5780601A (en) 1998-07-14
DK0606921T3 (da) 2000-09-04
ATE110965T1 (de) 1994-09-15
WO1990010458A1 (en) 1990-09-20
DE69012318D1 (de) 1994-10-13
AU5332690A (en) 1990-10-09
EP0606921B1 (de) 2000-08-02
EP0462210B1 (de) 1994-09-07
NO913518L (no) 1991-10-29
EP0606921A1 (de) 1994-07-20
JPH07508972A (ja) 1995-10-05
NO913518D0 (no) 1991-09-06
US6420134B1 (en) 2002-07-16
DE69033600D1 (de) 2000-09-07
US5601831A (en) 1997-02-11
CA2047681A1 (en) 1990-09-10

Similar Documents

Publication Publication Date Title
DE69033600D1 (de) Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
DE69631996D1 (de) Verfahren zur Herstellung von acylierten Proteinpuder
ATE126223T1 (de) Verfahren zur herstellung von ascorbinsäure.
DE3674739D1 (de) Verfahren zur herstellung von (2,2)-paracyclophan und dessen abkoemmlinge.
DE3762604D1 (de) Verfahren zur herstellung von waessrigen loesungen von freiem hydroxylamin.
DE3667489D1 (de) Verfahren zur herstellung eines proteins.
DE58905750D1 (de) Verfahren zur herstellung von konzentrierten fliessfaehigen waessrigen loesungen von betainen.
DE69023529T2 (de) Verfahren zur Behandlung von wässerigen Fermentationsbrühen.
DE69403210T3 (de) Verfahren zur herstellung von n-acetylneuraminsäure
DE3765556D1 (de) Transparente waesserige zinnverbindungsloesung und verfahren zur herstellung eines transparenten leitfaehigen zinnoxydes.
DE3861738D1 (de) Verfahren zur herstellung konzentrierter waessriger farbstoffzubereitungen.
DE3879049T2 (de) Verfahren zur Herstellung von Penizillan-Säurederivaten.
DE3671742D1 (de) Verfahren zur herstellung von dialkalisalzen der naphthalin-2,6-dicarbonsaeure.
DE3768426D1 (de) Verfahren zur herstellung von 4,4'-biphenyldicarbonsaeure.
DE3776440D1 (de) Verfahren zur herstellung von 5-aminosalicylsaeure.
DE255178T1 (de) Verfahren zur herstellung von heteroaryl- und arylalkansaeuren.
DE3784166T2 (de) Verfahren zur konzentration einer waesserigen loesung von aminosaeure.
DE3678487D1 (de) Verfahren zur herstellung von 6-amino-3-hydrazino-pyridazinderivaten.
ATE106893T1 (de) Verfahren zur herstellung von aktiviertem protein c.
DE3688201T2 (de) Verfahren zur herstellung von waessrigen loesungen von polysacchariden.
DE3763312D1 (de) Verfahren zur herstellung von hexaalkyldisilan.
JPS5559146A (en) Isolation of phenylalanine
DE3676899D1 (de) Verfahren zur herstellung von n-methyl-lysergol.
ATA136582A (de) Verfahren zur herstellung topisch applizierbarer pharmazeutischer praeparate, enthaltend salze von alkancarbonsaeuren
AT389227B (de) Verfahren zur herstellung einer chelatkomplexe von l-3,4-dihydroxyphenyl-alpha-methyl-alaninenthaltenden pharmazeutischen loesung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WYETH HOLDINGS CORP., MADISON, N.J., US